Cancer NetworkOriginal article
<![CDATA[Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma ]]>
Phase 1positivecevostamabpomalidomidedexamethasonePositive
AI Analysis
Summary
Cevostamab combined with pomalidomide and dexamethasone demonstrated durable responses with overall response rates of 86.2% to 88.0% in the phase 1b CAMMA 1 trial for relapsed/refractory multiple myeloma.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Outcome Details
Overall response rates of 86.2% to 88.0% in cevostamab combination therapy
Importance:6/10
Sentiment:
0.75
multiple myelomaphase 1bclinical trialcombination therapyoncology
Read the original article
Published by Cancer Network on September 24, 2026 9:00 PM